The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus

Triple-negative breast cancer (TNBC) is an aggressive and heterogeneous subgroup of breast tumors clinically defined by the lack of estrogen, progesterone and HER2 receptors, limiting the use of the targeted therapies employed in other breast malignancies. Recent evidence indicates that c-MYC is a k...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncotarget
Päätekijät: Vázquez, Ramiro, Riveiro, María E, Astorgues-Xerri, Lucile, Odore, Elodie, Rezai, Keyvan, Erba, Eugenio, Panini, Nicolò, Rinaldi, Andrea, Kwee, Ivo, Beltrame, Luca, Bekradda, Mohamed, Cvitkovic, Esteban, Bertoni, Francesco, Frapolli, Roberta, D'Incalci, Maurizio
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Impact Journals LLC 2016
Aiheet:
Research Paper
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352346/
https://ncbi.nlm.nih.gov/pubmed/27935867
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.13814
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia